Trader Puma Biotechnology, Inc. - PBYI CFD
Ajouter aux favoris- Résumé
- Données historiques
- Événements
- Compte de résultat
- Bilan
- Flux de trésorerie
- Capital
Conditions de trading
| Écart | 0.1142 | ||||||||
|
Frais de position longue en overnight
Long position overnight fee
Aller vers la plateforme | -0.025457% | ||||||||
|
Frais de position courte en overnight
Short position overnight fee
Aller vers la plateforme | 0.003235% | ||||||||
| Durée des frais en overnight | 21:00 (UTC) | ||||||||
| Quantité minimale négociée | 1 | ||||||||
| Devise | USD | ||||||||
| Marge | 20% | ||||||||
| Bourse | United States of America | ||||||||
| Commission sur la négociation | 0% |
*Information provided by Capital.com
Puma Biotechnology Inc ESG Risk Ratings
High Medium Low Negligible
‘C’ score indicates satisfactory relative ESG performance and moderate degree of transparency in reporting material ESG data publicly.
Chiffres clés
| Fermeture précédente* | 3.1993 |
| Ouvert* | 3.2283 |
| Variation sur 1 an* | 61.42% |
| Fourchette du jour* | 3.1896 - 3.3079 |
| Fourchette sur 52 semaines | 1.79-5.16 |
| Volume moyen (10 jours) | 248.13K |
| Volume moyen (3 mois) | 6.62M |
| Capitalisation boursière | 149.00M |
| Ratio C/B | 30.07 |
| Actions en circulation | 46.71M |
| Revenu | 235.07M |
| EPS | 0.11 |
| Dividende (rendement en %) | N/A |
| Bêta | 1.02 |
| Prochaine date de publication des résultats | Aug 2, 2023 |
Toutes les données sont fournies par Refinitiv, à l'exception des données marquées d'un astérisque, qui sont des *données fournies par Capital.com
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Clôture | Change | Change (%) | Ouverture | High | Low |
|---|---|---|---|---|---|---|
| May 30, 2023 | 3.1993 | 0.0695 | 2.22% | 3.1298 | 3.2389 | 3.0107 |
| May 26, 2023 | 3.1207 | 0.1891 | 6.45% | 2.9316 | 3.2093 | 2.9316 |
| May 25, 2023 | 3.1402 | -0.0187 | -0.59% | 3.1589 | 3.2192 | 2.8839 |
| May 24, 2023 | 3.1993 | 0.0404 | 1.28% | 3.1589 | 3.3269 | 3.0615 |
| May 23, 2023 | 3.2879 | 0.3261 | 11.01% | 2.9618 | 3.3866 | 2.8925 |
| May 22, 2023 | 2.9828 | 0.1789 | 6.38% | 2.8039 | 3.0026 | 2.8036 |
| May 19, 2023 | 2.8352 | 0.1889 | 7.14% | 2.6463 | 2.8549 | 2.6368 |
| May 18, 2023 | 2.6973 | -0.0676 | -2.44% | 2.7649 | 2.8057 | 2.6676 |
| May 17, 2023 | 2.7760 | -0.0195 | -0.70% | 2.7955 | 2.8155 | 2.7170 |
| May 16, 2023 | 2.7958 | -0.0087 | -0.31% | 2.8045 | 2.8943 | 2.7747 |
| May 15, 2023 | 2.8844 | 0.2089 | 7.81% | 2.6755 | 2.9140 | 2.6656 |
| May 12, 2023 | 2.7464 | -0.0968 | -3.40% | 2.8432 | 2.9238 | 2.6870 |
| May 11, 2023 | 2.9039 | -0.0185 | -0.63% | 2.9224 | 3.0223 | 2.8252 |
| May 10, 2023 | 3.0222 | 0.0219 | 0.73% | 3.0003 | 3.1306 | 2.9815 |
| May 9, 2023 | 3.0812 | 0.0509 | 1.68% | 3.0303 | 3.1503 | 3.0123 |
| May 8, 2023 | 3.1205 | 0.0994 | 3.29% | 3.0211 | 3.1405 | 2.8940 |
| May 5, 2023 | 3.0910 | 0.2366 | 8.29% | 2.8544 | 3.2192 | 2.8250 |
| May 4, 2023 | 2.5593 | 0.0900 | 3.64% | 2.4693 | 2.5989 | 2.4693 |
| May 3, 2023 | 2.5593 | 0.0315 | 1.25% | 2.5278 | 2.6678 | 2.5099 |
| May 2, 2023 | 2.5987 | 0.0410 | 1.60% | 2.5577 | 2.6381 | 2.4805 |
Puma Biotechnology, Inc. Events
| Heure (UTC) (UTC) | Pays | Événement |
|---|---|---|
| Tuesday, June 13, 2023 | ||
| Heure (UTC) (UTC) 17:00 | Pays US
| Événement Puma Biotechnology Inc Annual Shareholders Meeting Puma Biotechnology Inc Annual Shareholders MeetingForecast -Previous - |
| Wednesday, June 14, 2023 | ||
| Heure (UTC) (UTC) 20:00 | Pays US
| Événement Puma Biotechnology Inc Annual Shareholders Meeting Puma Biotechnology Inc Annual Shareholders MeetingForecast -Previous - |
| Wednesday, August 2, 2023 | ||
| Heure (UTC) (UTC) 10:59 | Pays US
| Événement Q2 2023 Puma Biotechnology Inc Earnings Release Q2 2023 Puma Biotechnology Inc Earnings ReleaseForecast -Previous - |
| Wednesday, November 1, 2023 | ||
| Heure (UTC) (UTC) 10:59 | Pays US
| Événement Q3 2023 Puma Biotechnology Inc Earnings Release Q3 2023 Puma Biotechnology Inc Earnings ReleaseForecast -Previous - |
- Annuel
- Trimestriel
| 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|
| Revenu total | 228.031 | 253.155 | 225.11 | 272.26 | 250.991 |
| Total des frais d'exploitation | 216.767 | 269.602 | 271.708 | 335.758 | 354.646 |
| Total des frais de vente/Généraux/Admin | 89.978 | 116.294 | 118.488 | 140.456 | 146.171 |
| Recherche et développement | 59.24 | 71.87 | 97.65 | 132.851 | 164.854 |
| Produits d'exploitation | 11.264 | -16.447 | -46.598 | -63.498 | -103.655 |
| Produits (charges) d'intérêts, nets Hors exploitation | -10.779 | -12.647 | -13.557 | -12.172 | -9.189 |
| Autres, nets | -0.028 | 0.292 | 0.367 | 0.128 | -0.714 |
| Résultat net avant impôts | 0.457 | -28.802 | -59.788 | -75.542 | -113.558 |
| Résultat net après impôts | 0.002 | -29.126 | -59.995 | -75.595 | -113.575 |
| Résultat net avant éléments extra | 0.002 | -29.126 | -59.995 | -75.595 | -113.575 |
| Résultat net | 0.002 | -29.126 | -59.995 | -75.595 | -113.575 |
| Revenu disponible pour les actionnaires ordinaires, hors éléments exceptionnels | 0.002 | -29.126 | -59.995 | -75.595 | -113.575 |
| Bénéfice disponible pour les actionnaires ordinaires, y compris les éléments exceptionnels | 0.002 | -29.126 | -59.995 | -75.595 | -113.575 |
| Résultat net dilué | 0.002 | -29.126 | -59.995 | -75.595 | -113.575 |
| Moyenne pondérée des actions diluées | 44.93 | 40.6389 | 39.5761 | 38.7687 | 37.9424 |
| BPA dilué hors éléments extraordinaires | 0.00004 | -0.7167 | -1.51594 | -1.9499 | -2.99335 |
| BPA dilué normalisé | 0.18024 | -0.43301 | -1.24994 | -1.52008 | -2.83917 |
| Revenu | 228.031 | 253.155 | 225.11 | 272.26 | 250.991 |
| Coût des recettes, total | 55.093 | 63.701 | 39.374 | 36.815 | 34.621 |
| Résultat brut | 172.938 | 189.454 | 185.736 | 235.445 | 216.37 |
| Total des éléments extraordinaires | |||||
| Charges (revenus) inhabituelles | 12.456 | 17.737 | 16.196 | 25.636 | 9 |
| Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | |
|---|---|---|---|---|---|
| Revenu total | 52.775 | 65.675 | 57.102 | 59.518 | 45.736 |
| Revenu | 52.775 | 65.675 | 57.102 | 59.518 | 45.736 |
| Coût des recettes, total | 13.218 | 16.836 | 12.495 | 14.918 | 10.844 |
| Résultat brut | 39.557 | 48.839 | 44.607 | 44.6 | 34.892 |
| Total des frais d'exploitation | 48.41 | 68.023 | 54.728 | 47.515 | 46.501 |
| Total des frais de vente/Généraux/Admin | 22.486 | 25.039 | 23.961 | 20.576 | 20.402 |
| Recherche et développement | 12.706 | 13.784 | 18.253 | 11.966 | 15.237 |
| Charges (revenus) inhabituelles | 0 | 12.364 | 0.019 | 0.055 | 0.018 |
| Produits d'exploitation | 4.365 | -2.348 | 2.374 | 12.003 | -0.765 |
| Produits (charges) d'intérêts, nets Hors exploitation | -2.775 | -2.76 | -2.731 | -2.637 | -2.651 |
| Autres, nets | -0.042 | -0.204 | 0.064 | 0.062 | 0.05 |
| Résultat net avant impôts | 1.548 | -5.312 | -0.293 | 9.428 | -3.366 |
| Résultat net après impôts | 1.401 | -5.606 | -0.36 | 9.371 | -3.403 |
| Résultat net avant éléments extra | 1.401 | -5.606 | -0.36 | 9.371 | -3.403 |
| Résultat net | 1.401 | -5.606 | -0.36 | 9.371 | -3.403 |
| Revenu disponible pour les actionnaires ordinaires, hors éléments exceptionnels | 1.401 | -5.606 | -0.36 | 9.371 | -3.403 |
| Bénéfice disponible pour les actionnaires ordinaires, y compris les éléments exceptionnels | 1.401 | -5.606 | -0.36 | 9.371 | -3.403 |
| Résultat net dilué | 1.401 | -5.606 | -0.36 | 9.371 | -3.403 |
| Moyenne pondérée des actions diluées | 47.1579 | 45.8267 | 45.5677 | 45.3587 | 42.2077 |
| BPA dilué hors éléments extraordinaires | 0.02971 | -0.12233 | -0.0079 | 0.2066 | -0.08063 |
| Dividends per Share - Common Stock Primary Issue | 0 | 0 | 0 | 0 | |
| BPA dilué normalisé | 0.02971 | 0.05304 | -0.00763 | 0.2078 | -0.08035 |
- Annuel
- Trimestriel
| 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|
| Total de l'actif à court terme | 134.281 | 140.022 | 146.139 | 166.296 | 203.003 |
| Espèces et placements à court terme | 81.074 | 82.106 | 93.389 | 111.644 | 165.421 |
| Trésorerie et équivalents | 76.201 | 63.131 | 85.293 | 60.037 | 108.419 |
| Investissements à court terme | 4.873 | 18.975 | 8.096 | 51.607 | 57.002 |
| Prepaid Expenses | 5.902 | 8.984 | 11.262 | 13.259 | 12.397 |
| Total Assets | 222.059 | 226.585 | 244.22 | 234.905 | 259.122 |
| Property/Plant/Equipment, Total - Net | 12.508 | 15.773 | 18.885 | 21.826 | 3.963 |
| Property/Plant/Equipment, Total - Gross | 19.934 | 22.634 | 25.036 | 27.685 | 9.139 |
| Accumulated Depreciation, Total | -7.426 | -6.861 | -6.151 | -5.859 | -5.176 |
| Other Long Term Assets, Total | 4.66 | 4.665 | 5.056 | 6.322 | 7.748 |
| Total Current Liabilities | 77.484 | 109.586 | 114.255 | 90.837 | 67.115 |
| Accounts Payable | 6.44 | 11.174 | 12.076 | 19.183 | 20.684 |
| Accrued Expenses | 69.674 | 96.149 | 85.412 | 71.654 | 46.431 |
| Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
| Total Liabilities | 200.451 | 229.031 | 250.171 | 217.442 | 224.816 |
| Total Long Term Debt | 98.307 | 97.092 | 84.025 | 94.962 | 151.886 |
| Other Liabilities, Total | 24.66 | 22.353 | 51.891 | 31.643 | 5.815 |
| Total Equity | 21.608 | -2.446 | -5.951 | 17.463 | 34.306 |
| Common Stock | 0.005 | 0.004 | 0.004 | 0.004 | 0.004 |
| Additional Paid-In Capital | 1388.36 | 1364.31 | 1331.68 | 1295.03 | 1236.35 |
| Retained Earnings (Accumulated Deficit) | -1366.76 | -1366.76 | -1337.63 | -1277.64 | -1202.04 |
| Other Equity, Total | 0 | -0.002 | 0 | 0.062 | -0.012 |
| Total Liabilities & Shareholders’ Equity | 222.059 | 226.585 | 244.22 | 234.905 | 259.122 |
| Total Common Shares Outstanding | 46.3457 | 41.1755 | 40.0864 | 39.2033 | 38.325 |
| Total des créances, nettes | 42.27 | 32.526 | 28.919 | 28.896 | 21.948 |
| Accounts Receivable - Trade, Net | 29.52 | 29.646 | 20.515 | 26.396 | 20.773 |
| Total Inventory | 4.526 | 7.109 | 3.454 | 3.17 | 2.625 |
| Intangibles, Net | 70.61 | 66.125 | 74.14 | 40.461 | 44.408 |
| Long Term Debt | 98.307 | 97.092 | 84.025 | 94.962 | 151.886 |
| Other Current Assets, Total | 0.509 | 9.297 | 9.115 | 9.327 | 0.612 |
| Current Port. of LT Debt/Capital Leases | 0 | 14.286 | |||
| Other Current Liabilities, Total | 1.37 | 2.263 | 2.481 |
| Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | |
|---|---|---|---|---|---|
| Total de l'actif à court terme | 111.753 | 134.281 | 122.353 | 114.28 | 117.57 |
| Espèces et placements à court terme | 71.217 | 81.074 | 77.96 | 60.754 | 73.907 |
| Trésorerie et équivalents | 61.394 | 76.201 | 77.96 | 52.756 | 63.913 |
| Investissements à court terme | 9.823 | 4.873 | 0 | 7.998 | 9.994 |
| Total des créances, nettes | 31.164 | 42.27 | 31.878 | 33.987 | 27.039 |
| Accounts Receivable - Trade, Net | 23.894 | 29.52 | 28.353 | 25.505 | 21.901 |
| Total Inventory | 3.891 | 4.526 | 5.452 | 6.665 | 7.277 |
| Prepaid Expenses | 5.032 | 5.902 | 6.801 | 8.583 | 8.716 |
| Other Current Assets, Total | 0.449 | 0.509 | 0.262 | 4.291 | 0.631 |
| Total Assets | 196.257 | 222.059 | 198.77 | 193.651 | 200.685 |
| Property/Plant/Equipment, Total - Net | 11.669 | 12.508 | 13.335 | 14.158 | 14.964 |
| Property/Plant/Equipment, Total - Gross | 19.222 | 19.934 | 20.625 | 21.295 | 21.945 |
| Accumulated Depreciation, Total | -7.553 | -7.426 | -7.29 | -7.137 | -6.981 |
| Intangibles, Net | 68.175 | 70.61 | 60.114 | 62.118 | 64.121 |
| Other Long Term Assets, Total | 4.66 | 4.66 | 2.968 | 3.095 | 4.03 |
| Total Current Liabilities | 48.188 | 77.484 | 59.987 | 56.834 | 74.789 |
| Accounts Payable | 8.589 | 6.44 | 14.927 | 9.841 | 7.412 |
| Accrued Expenses | 38.432 | 69.674 | 43.679 | 45.137 | 65.535 |
| Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
| Current Port. of LT Debt/Capital Leases | |||||
| Other Current Liabilities, Total | 1.167 | 1.37 | 1.381 | 1.856 | 1.842 |
| Total Liabilities | 170.41 | 200.451 | 176.615 | 173.913 | 193.54 |
| Total Long Term Debt | 98.623 | 98.307 | 97.994 | 97.682 | 97.381 |
| Long Term Debt | 98.623 | 98.307 | 97.994 | 97.682 | 97.381 |
| Other Liabilities, Total | 23.599 | 24.66 | 18.634 | 19.397 | 21.37 |
| Total Equity | 25.847 | 21.608 | 22.155 | 19.738 | 7.145 |
| Common Stock | 0.005 | 0.005 | 0.005 | 0.005 | 0.004 |
| Additional Paid-In Capital | 1391.2 | 1388.36 | 1383.3 | 1380.52 | 1377.3 |
| Retained Earnings (Accumulated Deficit) | -1365.35 | -1366.76 | -1361.15 | -1360.79 | -1370.16 |
| Total Liabilities & Shareholders’ Equity | 196.257 | 222.059 | 198.77 | 193.651 | 200.685 |
| Total Common Shares Outstanding | 46.6636 | 46.3457 | 45.6088 | 45.2746 | 44.9494 |
| Other Equity, Total | 0 | 0 | 0 | -0.001 |
- Annuel
- Trimestriel
| 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|
| Revenu net/Ligne de départ | 0.002 | -29.126 | -59.995 | -75.595 | -113.575 |
| Liquidités provenant des activités d'exploitation | -15.827 | 20.65 | 0.773 | 22.376 | -24.105 |
| Liquidités provenant des activités d'exploitation | 8.92 | 10.598 | 10.033 | 8.077 | 7.384 |
| Éléments non monétaires | 18.827 | 39.78 | 37.575 | 66.611 | 87.228 |
| Intérêts payés en espèces | 10.319 | 10.342 | 9.703 | 11.739 | 8.055 |
| Variation du fonds de roulement | -43.576 | -0.602 | 13.16 | 23.283 | -5.142 |
| Flux de trésorerie liés aux activités d'investissement | 7.104 | -10.881 | 23.403 | 5.163 | -57.623 |
| Dépenses d'investissement | -7 | 0 | -20.046 | -0.306 | -0.609 |
| Autres éléments de flux de trésorerie d'investissement, total | 14.104 | -10.881 | 43.449 | 5.469 | -57.014 |
| Flux de trésorerie provenant des activités de financement | 12.223 | -31.931 | 0.068 | -67.067 | 108.451 |
| Éléments de flux de trésorerie de financement | 0 | -30.431 | 0 | -13.418 | -4.201 |
| Émission (remboursement) d'actions, nette | 12.223 | 0 | 0.068 | 1.351 | 7.652 |
| Émission (remboursement) de la dette, nette | 0 | -1.5 | 0 | -55 | 105 |
| Variation nette de la trésorerie | 3.5 | -22.162 | 24.244 | -39.528 | 26.723 |
| Cash Taxes Paid | 0.384 | 0.324 | 0.207 |
| Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | |
|---|---|---|---|---|---|
| Net income/Starting Line | 1.401 | 0.002 | 5.608 | 5.968 | -3.403 |
| Cash From Operating Activities | 2.643 | -15.827 | -23.51 | -40.769 | -26.895 |
| Cash From Operating Activities | 2.878 | 8.92 | 6.713 | 4.486 | 2.262 |
| Non-Cash Items | 2.838 | 18.827 | 9.199 | 6.369 | 3.149 |
| Cash Taxes Paid | 0.142 | 0.384 | 0.141 | 0.141 | 0 |
| Cash Interest Paid | 2.907 | 10.319 | 7.412 | 4.776 | 2.375 |
| Changes in Working Capital | -4.474 | -43.576 | -45.03 | -57.592 | -28.903 |
| Cash From Investing Activities | -17.45 | 7.104 | 18.977 | 10.979 | 8.982 |
| Other Investing Cash Flow Items, Total | -4.95 | 14.104 | 18.977 | 10.979 | 8.982 |
| Net Change in Cash | -14.807 | 3.5 | 5.259 | -19.945 | -8.068 |
| Cash From Financing Activities | 0 | 12.223 | 9.792 | 9.845 | 9.845 |
| Issuance (Retirement) of Debt, Net | 0 | 0 | 0 | ||
| Capital Expenditures | -12.5 | -7 | |||
| Financing Cash Flow Items | 0 | 0 | 0 | -0.155 | -0.155 |
| Issuance (Retirement) of Stock, Net | 0 | 12.223 | 9.792 | 10 | 10 |
| Nom de l'investisseur | Catégorie de l'investisseur | Pourcentage de l'encours | Actions détenues | Changement d'actions | Date d'avoirs | Taux du chiffre d'affaires |
|---|---|---|---|---|---|---|
| Auerbach (Alan H) | Individual Investor | 14.3838 | 6718247 | -888975 | 2023-04-19 | LOW |
| Camber Capital Management LP | Hedge Fund | 9.0672 | 4235000 | 0 | 2023-03-31 | MED |
| The Vanguard Group, Inc. | Investment Advisor/Hedge Fund | 8.0745 | 3771345 | 182423 | 2023-03-31 | LOW |
| Millennium Management LLC | Hedge Fund | 6.3927 | 2985835 | 308922 | 2023-03-31 | HIGH |
| Eversept Partners, LP | Hedge Fund | 4.1495 | 1938088 | 430425 | 2023-03-31 | MED |
| Acadian Asset Management LLC | Investment Advisor/Hedge Fund | 4.0141 | 1874859 | 61819 | 2023-03-31 | MED |
| Renaissance Technologies LLC | Hedge Fund | 3.9286 | 1834913 | 136070 | 2023-03-31 | HIGH |
| Athyrium Capital Management, LP | Investment Advisor/Hedge Fund | 3.8369 | 1792114 | 0 | 2023-03-31 | LOW |
| BlackRock Institutional Trust Company, N.A. | Investment Advisor | 2.1727 | 1014811 | -2440 | 2023-03-31 | LOW |
| Hillsdale Investment Management Inc. | Investment Advisor/Hedge Fund | 1.7858 | 834103 | 167897 | 2023-03-31 | MED |
| Two Sigma Investments, LP | Hedge Fund | 1.2605 | 588749 | 29399 | 2023-03-31 | HIGH |
| GlobeFlex Capital, L.P. | Investment Advisor | 1.2022 | 561530 | 0 | 2023-03-31 | MED |
| Kynam Capital Management LP | Hedge Fund | 1.0128 | 473070 | -88539 | 2023-03-31 | MED |
| Susquehanna International Group, LLP | Investment Advisor | 0.9896 | 462196 | 202786 | 2023-03-31 | MED |
| Dimensional Fund Advisors, L.P. | Investment Advisor/Hedge Fund | 0.9701 | 453105 | 220336 | 2023-03-31 | LOW |
| BlackRock Financial Management, Inc. | Investment Advisor/Hedge Fund | 0.9567 | 446855 | -25 | 2023-03-31 | LOW |
| Geode Capital Management, L.L.C. | Investment Advisor/Hedge Fund | 0.8385 | 391622 | 10711 | 2023-03-31 | LOW |
| Rice Hall James & Associates, LLC | Investment Advisor/Hedge Fund | 0.7868 | 367497 | -15721 | 2023-03-31 | LOW |
| SEI Investments Management Corporation | Investment Advisor/Hedge Fund | 0.6125 | 286060 | -105 | 2023-03-31 | LOW |
| EAM Investors, LLC | Investment Advisor/Hedge Fund | 0.584 | 272787 | 272787 | 2022-12-31 | HIGH |
Pourquoi choisir capital.com? Nos chiffres parlent d'eux-mêmes.
Capital.com Group530K+
Tradeurs
87K+
Clients actifs par mois
$46M+
Volume d'investissement par mois
$31M+
Retrait par mois
Trading calculator
Calculez votre P&L hypothétique si vous aviez ouvert une transaction CFD à une certaine date (sélectionnez une date) et l'aviez fermée à une autre date (sélectionnez une date).
Trade commission
0
- 1:1
Effet de levier
1:1
- 20
- 100
- 500
- 1000
- 10000
Investment
Trade size (Leverage x Investement):
Ouverture
Clôture
Short Long
Puma Biotechnology Company profile
À propos de Puma Biotechnology, Inc.
Puma Biotechnology, Inc. est une société biopharmaceutique. La Société se concentre sur le développement et la commercialisation de produits destinés à améliorer le traitement du cancer. Le produit phare de la Société est NERLYNX, une version orale du nératinib, un puissant inhibiteur irréversible de la tyrosine kinase (ITK) qui bloque la transduction du signal par les récepteurs du facteur de croissance épidermique humain, HER1, HER2 et HER4. L'entreprise se concentre principalement sur le développement et la commercialisation de la version orale du nératinib, et ses médicaments candidats avancés sont destinés au traitement du cancer du sein HER2-positif et des cancers mutés HER2. Ses autres produits comprennent le PB272 (nératinib, intraveineux), le PB357 et certains composés connexes. Son nératinib a une application clinique dans le traitement de plusieurs autres cancers, y compris d'autres types de tumeurs qui surexpriment ou présentent une mutation de HER2 ou du récepteur du facteur de croissance épidermique (EGFR), comme le cancer du sein, le cancer du col de l'utérus, le cancer du poumon ou d'autres tumeurs solides.
| Industry: | Biotechnology & Medical Research (NEC) |
Suite 2150
10880 Wilshire Blvd.
LOS ANGELES
CALIFORNIA 90024
US
Compte de résultat
- Annual
- Quarterly
Les gens regardent aussi
Êtes-vous toujours à la recherche d'un broker de confiance?
Rejoignez les plus de 530 000 traders du monde entier qui ont choisi de trader avec Capital.com